REVIEW

Transporting mitochondria in neurons [version 1; peer review: 2 approved]

Meredith M. Course^{1,2}, Xinnan Wang¹

¹Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA, USA

²Neurosciences Graduate Program, Stanford University, Stanford, CA, USA

V1 First published: 18 Jul 2016, 5(F1000 Faculty Rev):1735
<https://doi.org/10.12688/f1000research.7864.1>

Latest published: 18 Jul 2016, 5(F1000 Faculty Rev):1735
<https://doi.org/10.12688/f1000research.7864.1>

Abstract

Neurons demand vast and vacillating supplies of energy. As the key contributors of this energy, as well as primary pools of calcium and signaling molecules, mitochondria must be where the neuron needs them, when the neuron needs them. The unique architecture and length of neurons, however, make them a complex system for mitochondria to navigate. To add to this difficulty, mitochondria are synthesized mainly in the soma, but must be transported as far as the distant terminals of the neuron. Similarly, damaged mitochondria—which can cause oxidative stress to the neuron—must fuse with healthy mitochondria to repair the damage, return all the way back to the soma for disposal, or be eliminated at the terminals. Increasing evidence suggests that the improper distribution of mitochondria in neurons can lead to neurodegenerative and neuropsychiatric disorders. Here, we will discuss the machinery and regulatory systems used to properly distribute mitochondria in neurons, and how this knowledge has been leveraged to better understand neurological dysfunction.

Keywords

mitochondria , neurons, Transporting mitochondria , dynein , Myosins

Open Peer Review

Approval Status

	1	2
version 1 18 Jul 2016

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Michael B. Robinson**, University of Pennsylvania, Philadelphia, USA

2. **Eugenia Trushina**, Mayo Clinic, Rochester, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Xinnan Wang (xinnanw@stanford.edu)

Competing interests: The author(s) declared that they have no competing interests.

Grant information: This work was supported by the Alfred P. Sloan Foundation (Xinnan Wang), the Klingenstein Foundation (Xinnan Wang), the California Institute of Regenerative Medicine (Xinnan Wang), the National Institutes of Health (RO1NS089583) (Xinnan Wang), and the Graduate Research Fellowship Program of the National Science Foundation (Meredith M. Course).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2016 Course MM and Wang X. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Course MM and Wang X. **Transporting mitochondria in neurons [version 1; peer review: 2 approved]** F1000Research 2016, 5(F1000 Faculty Rev):1735 <https://doi.org/10.12688/f1000research.7864.1>

First published: 18 Jul 2016, 5(F1000 Faculty Rev):1735 <https://doi.org/10.12688/f1000research.7864.1>

Introduction

The transport of mitochondria is critical to a neuron's health. Although frequently referred to as "the powerhouse of the cell", mitochondria do much more than produce ATP. In addition to being the cell's major energy provider, mitochondria are responsible for storing and buffering Ca^{2+} , detoxifying ammonia, and producing some steroids¹, heme compounds², heat, and reactive oxygen species. They are vital to the metabolism of neurotransmitters glutamate and gamma-aminobutyric acid (GABA)³, and send signals for apoptosis, proliferation, and cell survival⁴. They even boast their own DNA and protein synthesis machinery as a vestige of their previous life as bacteria. It is thus unsurprising to learn that precise control of mitochondrial number, health, and distribution is especially critical to the neuron, which is a complex cell with high energy and regulatory demands.

Several features distinguish neurons from other cells. First, they have a long, thin axon—the longest axon in the human body can extend over one meter—and contain many areas of sub-specialization, like the pre-synapse, post-synapse, growth cones, and nodes of Ranvier⁵, each with different metabolic needs. Second, as the carriers of synaptic information, neurons have ever-changing energy and Ca^{2+} buffering demands, especially at their terminals. Finally, because neurons are post-mitotic and will stay with the organism for the duration of its life, they must be protected from excitotoxicity and kept in a state of homeostasis as long as possible. The appropriate allocation and sustenance of mitochondria are essential to fulfilling the many demands of the neuron, and keeping it in good health.

To meet the vacillating needs of neurons, about 30% to 40% of these spry organelles are in motion at any given time^{6–9}. Properly distributing mitochondria throughout a neuron, however, is complicated by the fact that mitochondria are primarily produced in the soma, with most of their proteins encoded by nuclear DNA, but are needed as far away as the synaptic terminal. Static mitochondria pool at or near synapses, which may be important for rapid neuronal firing, while passing mitochondria may be recruited to support prolonged energy needs and repetitive neuronal firing^{10–12}. Additionally, damaged mitochondria produce reactive oxygen species, which can be toxic to the cell, and these dysfunctional mitochondria must be repaired by fusing with new mitochondria transported from the soma, be returned to the soma for degradation in a process termed mitophagy, or be cleared through mitophagy in neurites *in situ*¹³. Whether providing a service to the neuron, or needing clearance to prevent damage to the neuron, mitochondria must travel long distances and know precisely where and when to stop. When their transport machinery breaks down or signals regulating this machinery cannot be relayed, the consequence can be injury to or even death of the neuron^{9,14–17}. Here we will review the molecular mechanisms underlying mitochondrial transport in neurons, and what happens when they are disrupted.

Transport machinery

Much like a train, organelle transport requires a track, a motor, and a cargo. For mitochondria—the cargo—the overwhelming majority of their tracks are microtubules, which in mammalian neurons have their plus ends oriented toward the axon terminal,

and their minus ends toward the soma (although this homogeneity is not the case in dendrites)^{18–20}. This uniform polarity makes neuronal axons an especially useful model for studying organelle transport. The motors used to transport mitochondria depend on the direction in which they need to travel. In general, mitochondria move in the anterograde direction (away from the soma) using a family of kinesin motors, and move in the retrograde direction (toward the cell body) using the dynein motor²¹. While kinesins and dynein are also used to carry other cargos, the motor adaptors that anchor the motor and cargo together are cargo-specific, allowing for the regulation of movement by particular cellular signals. In addition to microtubules, mitochondrial movement can be powered along actin filaments by myosin motors, a process that is required for short-range movement, and for opposing movement along the microtubules^{22–24}.

Anterograde movement with the kinesin heavy chain complex

The best-characterized mitochondrial transport complex to date uses kinesin heavy chain (KHC, a member of the kinesin-1 family) as its motor, and Miro and Milton as its motor adaptors. Miro stands for "mitochondrial Rho" and belongs to the atypical Rho (Ras homolog) family of GTPases (RhoT1/2 in mammals). Miro is anchored to the outer mitochondrial membrane (OMM) via its carboxy-terminus transmembrane domain. Miro binds to Milton (trafficking protein, kinase-binding, or TRAK1/2 in mammals), which in turn binds to the carboxy-terminus of KHC^{25–27}. Milton was identified in a *Drosophila* screen for blind flies and was named after the great poet and polemicist John Milton, who was also blind²⁸. Together, Miro and Milton facilitate anterograde mitochondrial movement along microtubules by connecting mitochondria to KHC (Figure 1a). When either Miro or Milton is mutated in animal models, mitochondria are trapped in the soma and lose the ability to move out into the axons^{9,14–16,26,28}.

Miro and Milton are not the only adaptors that can link mitochondria and KHC. Syntabulin can bind directly to the OMM and KHC, and disruption of syntabulin function has been shown to inhibit the anterograde transport of mitochondria in neurons²⁹. Similarly, disrupting fasciculation and elongation protein zeta-1 (FEZ1), and RAN-binding protein 2 (RANBP2) also affects mitochondrial distribution because of their association with kinesins, possibly KIF3A and KIF5B/C, respectively^{30–34}.

Mutations in KHC have been shown to reduce anterograde mitochondrial movement but do not eliminate it entirely, which suggests that other kinesin motors may also play a role in anterograde mitochondrial motility²¹. For example, kinesins from the Kinesin-3 family KIF1B α and KLP6 may interact with KIF1 binding protein (KBP) to transport mitochondria^{35–38}. KIF1B can transport mitochondria along microtubules *in vitro*, and mutations in *Klp6* inhibits anterograde mitochondrial motility into neurites; however, the roles of these other kinesins await further clarification.

Retrograde movement with the dynein complex

Dynein is thought to act as the retrograde motor for microtubule-based mitochondrial movement, although far less is known about the mechanisms underlying its action. In contrast to the host of

Figure 1. Schematic representation of mitochondrial transport machinery. (a) The primary motor/adaptor complex mediating anterograde mitochondrial transport along microtubules (purple), including kinesin heavy chain (KHC) (red), Miro (orange), and Milton (blue). (b) The machinery mediating retrograde mitochondrial transport along microtubules (purple), including dynein (green), dynactin (gold), and a potential motor adaptor, Protein X (pink). Protein X could be the Milton/Miro complex³⁹. (c) Mitochondrial movement along actin filaments (olive), using a myosin motor (fuschia) and a potential motor adaptor, Protein X (yellow).

kinesins available for anterograde transport, there is only one identified dynein motor; however, dynein's larger and more complex structure has made it difficult to study. Dynein has been shown to form a complex with dynactin, and this complex has been shown to also interact with Milton/TRAK2 and with Miro³⁹, which lends support to dynein's role in mitochondrial transport (Figure 1b). Interestingly, dynein movement is also thought to depend on kinesin-1, as mutation in kinesin-1 reduces retrograde movement of mitochondria²¹.

Actin-based movement with myosin complexes

A small though not insignificant number of mitochondria are also transported along actin filaments²². This is more common in actin-enriched neuronal compartments, like growth cones, dendritic spines, and synaptic boutons. Myosins are actin-based motors, and the myosin Myo19 has been shown to anchor directly to the OMM, and regulate mitochondrial motility^{24, 40}. Myosins V and VI have also been shown to play a role in mitochondrial motility by opposing microtubule-based mitochondrial transport²³, although whether these myosin motors attach directly to mitochondria or require a motor adaptor remains unknown (Figure 1c). WAVE1 (WASP family verprolin homologous protein 1), which regulates actin polymerization, has been shown to be critical for mitochondrial transport in dendritic spines and filopodia—areas that are actin-rich—and therefore may be involved in the actin-based transport of mitochondria⁴¹.

Anchoring mitochondria

If 30% to 40% of mitochondria are in motion at any given time, then more than half of mitochondria are static. While

understanding of how stationary pools of mitochondria are generated is still nascent, one protein, syntaphilin, stands out. Syntaphilin serves as a molecular brake, docking mitochondria by binding to both the mitochondrial surface and to the microtubule⁴². Both kinesin-1 and the dynein light chain component LC8 have been shown to regulate this mechanism^{43,44}. Intriguingly, a recent study using optogenetics has shown that the mitochondrial dance between mobility and stabilization depends on the balance of forces between motors and anchors, rather than all-or-none switching⁴⁵.

Regulation of the kinesin heavy chain/Milton/Miro complex

Ca²⁺

The ability of mitochondria to temporarily stop where they are needed is just as important as their ability to move. When cytosolic Ca²⁺ concentration is elevated, Ca²⁺ binds to the EF hands of Miro and triggers a transient and instantaneous conformational change in the KHC/Milton/Miro complex. This conformational change causes dissociation of either the whole complex from microtubules⁹, or KHC from mitochondria¹⁷, which arrests movement of mitochondria. When Ca²⁺ concentration is lowered, Ca²⁺ is removed from Miro, and mitochondria are reattached to microtubules by the complex and can start moving again. The sensitivity of mitochondrial movement to Ca²⁺ is likely a means by which mitochondria can be recruited to areas of high metabolic demand or low local ATP, like post-synaptic specializations and growth cones. During glutamate receptor activation, mitochondria are recruited where Ca²⁺ influx is increased, which confers neurons with resistance to excitotoxicity^{9,17}. Interestingly, brain-derived

neurotrophic factor (BDNF) has recently been shown to arrest mitochondrial motility via Ca^{2+} binding to Miro1 in cultured hippocampal neurons⁴⁶.

Glucose

Glucose has recently been shown to influence mitochondrial motility via the KHC/milton/Miro complex. The small sugar UDP-GlcNAc is derived from glucose through the hexamine biosynthetic pathway. UDP-GlcNAc is affixed to milton by *O*-GlcNAc transferase (OGT), in a process called *O*-GlcNAcylation⁴⁷. Extracellular glucose concentration or OGT activity can modulate mitochondrial motility through *O*-GlcNAcylation of milton. This mechanism links nutrient availability to mitochondrial distribution, which could be a mechanism by which neurons maintain a balanced metabolic state.

PINK1/Parkin

When mitochondria are severely damaged, they undergo mitophagy, a crucial cellular mechanism that eliminates depolarized mitochondria through autophagosomes and lysosomes. Damaged mitochondria must be stopped prior to the initiation of mitophagy. To accomplish this, mitochondrial depolarization activates PINK1 (PTEN-induced putative kinase 1)-mediated phosphorylation of Miro^{16,48}, which subsequently triggers Parkin-dependent proteasomal degradation of Miro, thus releasing the mitochondria from its microtubule motors^{16,49}. It is likely that stopping mitochondria in this manner is an early step in the quarantine of damaged mitochondria before degradation. In fact, this PINK1-mediated phosphorylation of Miro has been shown to protect dopaminergic neurons *in vivo* in *Drosophila*⁵⁰. PINK1 and Parkin can also work in concert to remove damaged mitochondria through local mitophagy in distal axons, which would obviate the need for the mitochondria to be transported all the way back to the soma, and instead require the recruitment of autophagosomes to the damaged mitochondria¹³. How a cell chooses between transporting a mitochondrion back to the soma or using local mitophagy when it is damaged in the axon remains an outstanding question.

The dynamics of mitochondrial fission and fusion also plays a central role in PINK1/Parkin-mediated mitophagy. For example, mitofusin, a large GTPase that regulates mitochondrial fusion, is a target of the PINK1/Parkin pathway. Degradation of mitofusin prevents mitochondria from being able to fuse, and they instead fragment, a critical step prior to mitophagy^{51–55}. An in-depth discussion of the role of mitochondrial dynamics in quality control merits its own review, and an excellent F1000 Faculty Review and two others are recommended in the References section^{56–58}.

Other milton/Miro regulators

In humans, milton is encoded by two different genes: *TRAK1* and *TRAK2*. It has been reported that TRAK1 binds to both kinesin-1 and dynein, while TRAK2 predominantly favors dynein³⁹. In *Drosophila*, milton has several splicing variants, one of which (milton-C) does not bind to KHC²⁶. These varying forms of milton may play an important role in regulating the KHC/milton/Miro complex.

Another regulator that merits mentioning is HUMMR (hypoxia up-regulated mitochondrial movement regulator), whose expression is induced by hypoxic conditions. HUMMR has been shown to interact with the KHC/milton/Miro complex, and increases the ratio of anterograde to retrograde movement of mitochondria⁵⁹. Similarly, a family of proteins encoded by an array of armadillo (Arm) repeat-containing genes has been shown to bind to milton/Miro and regulate mitochondrial motility⁶⁰.

It is worthwhile to note that mitochondrial fission and fusion also affect mitochondrial motility. The same mitofusin mentioned previously also binds to milton/Miro, and knockdown of mitofusin 2 has been shown to inhibit mitochondrial motility⁶¹. Additionally, transient fusion has been shown to promote mitochondrial movement⁶².

Other regulators

The list of possible mitochondrial transport regulators burgeons daily, although thorough mechanisms remain scarce. For example, nerve growth factor can cause accumulation of mitochondria to its site of application^{63,64}. Another growth factor, lysophosphatidic acid, can inhibit mitochondrial movement⁶⁵. Intracellular ATP levels regulate mitochondrial motility, which decreases when close to synapses, and local production of ADP can recruit more mitochondria to areas requiring more ATP^{66,67}. Increased cAMP can increase mitochondrial motility⁶⁸. Pharmacological activation of AMP-activated protein kinase (AMPK) can promote anterograde movement of mitochondria for the formation of axon branches⁶⁹. Activation of the serotonin receptor increases mitochondrial movement via the AKT-GSK3 β (Akt-glycogen synthase kinase 3 β) pathway⁶, and conversely, dopamine and activation of the dopamine receptor D2 can inhibit mitochondrial movement via the same AKT-GSK3 β pathway^{70,71}. One recent study shows that GSK-3 β directly regulates dynein⁷², while another study shows that it promotes anterograde movement⁶⁸. This list of molecules likely skims the surface of all the signals and sensors involved in mitochondrial motility, which are yet to be uncovered.

Implications for neurological disorders

Because mitochondria are critical for energy production, calcium buffering, and cell survival pathways, it is not surprising to learn that impaired mitochondrial movement has been linked to neuronal dysfunction and neurological disorders^{73–75}. The long distance travelled by mitochondria in neurons, as compared to in other cells, may account for the fact that neurons are more vulnerable to impairments in mitochondrial transport. Altered mitochondrial motility may provide an early indication of neuronal pathology prior to cell death, either because motility is directly affected or because it is altered as a consequence of other mitochondrial malfunctions.

Neurodegenerative diseases

Aging itself has been shown to decrease neuronal mitochondrial motility in mice, and several age-dependent neurodegenerative diseases have been linked to mitochondrial motility defects⁷⁶. Mutations in the previously mentioned *PINK1* and *Parkin* are

both causes of familial Parkinson's disease (PD)^{77,78}. In individuals lacking either functional PINK1 or Parkin, a failure to isolate, stop, and remove the damaged mitochondria may contribute to neuronal cell death. Unpublished work using patients' samples from our laboratory also suggests that neurodegeneration in non-*PINK1/Parkin*-related PD cases may arise in a similar manner, and that stopping damaged mitochondrial motility is neuroprotective. This finding highlights the broader implications of mitochondrial motility in neuronal health and pathology.

The pathological forms of amyloid beta and tau, the chief markers of Alzheimer's disease (AD), have both been shown to inhibit mitochondrial motility in several AD models^{79–83}. Superoxide dismutase 1, soluble (SOD1), fused in sarcoma (FUS), C9orf72, and TAR DNA-binding protein 43 (TDP-43) mutations, which cause familial amyotrophic lateral sclerosis (also called Lou Gehrig's disease), have also been shown to impair mitochondrial transport in mice, flies, and cultured neuronal models^{84–91}. Mutant huntingtin protein, with the polyglutamine expansions characteristic of Huntington's disease etiology, can act to "jam traffic" by mechanical obstruction, and may also bind to miltion or even to the mitochondria itself to disrupt mitochondrial motility^{92–94}. Mutations in *mitofusin 2* causing Charcot-Marie-Tooth disease alter mitochondria movement⁹⁵, and finally, mitochondrial motility defects have also been observed in models of hereditary spastic paraplegia, a disease characterized by axonal degeneration^{96,97}.

Neuropsychiatric disorders

A few psychiatric disorders have also been linked to mitochondrial motility defects. Mutations in disrupted in schizophrenia 1 (*DISC1*) may contribute to both schizophrenia and some forms of depression⁹⁸. *DISC1* complexes with TRAK1/miltion and Miro1 to modulate anterograde transport of mitochondria^{99,100}, and its interactors NDE1 and GSK3 β have recently been shown to associate with TRAK1/miltion and similarly play a role in mitochondrial motility⁶⁸. *DISC1* also interacts with the previously mentioned FEZ1¹⁰¹, which binds to kinesins^{25,28}. Among several causes, depression can be attributed to a loss of serotonin¹⁰². Interestingly, the application of serotonin to cultured hippocampal neurons has been shown to increase mitochondrial motility⁶.

Closing remarks

The proper transport of mitochondria in neurons is critical to the homeostasis of the cell. Many questions in this field, however, remain to be answered. On a basic level of investigation, a more thorough understanding of the machinery—like the dynein motor, myosin motors, and the signals and adaptors that regulate this complex system—is still desperately needed.

A significant higher-level question is: how does the cell decide what to do with a damaged mitochondrion in the distal segment of an axon? The cell has several options: return the mitochondria to the soma for lysosomal degradation, which requires long-distance retrograde transport; degrade the mitochondrion via local mitophagy, which requires recruitment of autophagosomes to

mitochondria and fusion of autophagosomes with lysosomes in the axon; or send a healthy mitochondrion from the soma via anterograde transport to repair the damage by fusing with the unhealthy mitochondrion. Could this decision be made on the basis of the nature or severity of the damage to the mitochondrion? Does this decision take into account the relative energy expended? What are the signals and molecules that execute this decision? These actions must also be influenced by the local metabolic state, *de novo* protein synthesis, and neuronal activity in extremities far from the cell body.

It is also crucial to explore the translational implications of these findings. What of this knowledge can be leveraged for therapeutic benefit? Perhaps mitochondrial motility could be used as a novel phenotypic readout to screen for more effective treatments for neurological disorders, as well as a way to diagnose the disease and monitor its progression. A more comprehensive understanding of the molecular mechanisms underlying mitochondrial transport will prove invaluable as it provides novel targets, like the KHC/miltion/Miro complex, for diagnostic innovation and therapeutic intervention.

Most knowledge of mitochondrial movement in neurons has been uncovered using cultured rodent neurons. The application of emerging *in vivo* models will shed light on the physiological significance of the regulation of mitochondrial motility^{76,103–107}. Therefore, imaging mitochondria in living animals, especially during development and aging, as well as under disease conditions, will be an important step for the field.

Finally, given the inseparable relationship between neuronal function and metabolism, and mitochondrial motility and distribution, their underlying regulatory mechanisms must be interwoven. How do action potentials, neuronal signaling molecules like dopamine and serotonin, or metabolites like glucose, fatty acids, and amino acids influence mitochondrial motility and distribution? And how do mitochondrial motility and function reciprocally control neuronal homeostasis? Answers to these questions will reveal how neurons respond to changes in their activities and environments by regulating this cellular linchpin.

Competing interests

The authors declare that they have no competing interests.

Grant information

This work was supported by the Alfred P. Sloan Foundation (Xinnan Wang), the Klingenstein Foundation (Xinnan Wang), the California Institute of Regenerative Medicine (Xinnan Wang), the National Institutes of Health (RO1NS089583) (Xinnan Wang), and the Graduate Research Fellowship Program of the National Science Foundation (Meredith M. Course).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Rossier MF: **T channels and steroid biosynthesis: in search of a link with mitochondria.** *Cell Calcium*. 2006; **40**(2): 155–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Oh-hama T: **Evolutionary consideration on 5-aminolevulinate synthase in nature.** *Orig Life Evol Biosph*. 1997; **27**(4): 405–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Kugler P, Baier G: **Mitochondrial enzymes related to glutamate and GABA metabolism in the hippocampus of young and aged rats: a quantitative histochemical study.** *Neurochem Res*. 1992; **17**(2): 179–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. McBride HM, Neuspiel M, Wasiak S: **Mitochondria: more than just a powerhouse.** *Curr Biol*. 2006; **16**(14): R551–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. **F** Ohno N, Kidd GJ, Mahad D, *et al.*: **Myelination and axonal electrical activity modulate the distribution and motility of mitochondria at CNS nodes of Ranvier.** *J Neurosci*. 2011; **31**(20): 7249–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
6. Chen S, Owens GC, Crossin KL, *et al.*: **Serotonin stimulates mitochondrial transport in hippocampal neurons.** *Mol Cell Neurosci*. 2007; **36**(4): 472–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Overly CC, Rieff HI, Hollenbeck PJ: **Organelle motility and metabolism in axons vs dendrites of cultured hippocampal neurons.** *J Cell Sci*. 1996; **109**(Pt 5): 971–80.
[PubMed Abstract](#)
8. Waters J, Smith SJ: **Mitochondria and release at hippocampal synapses.** *Pflügers Arch*. 2003; **447**(3): 363–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. **F** Wang X, Schwarz TL: **The mechanism of Ca²⁺-dependent regulation of kinesin-mediated mitochondrial motility.** *Cell*. 2009; **136**(1): 163–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
10. **F** Li Z, Okamoto K, Hayashi Y, *et al.*: **The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses.** *Cell*. 2004; **119**(6): 873–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
11. **F** Verstreken P, Ly CV, Venken KJ, *et al.*: **Synaptic mitochondria are critical for mobilization of reserve pool vesicles at *Drosophila* neuromuscular junctions.** *Neuron*. 2005; **47**(3): 365–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
12. Chang DT, Honick AS, Reynolds IJ: **Mitochondrial trafficking to synapses in cultured primary cortical neurons.** *J Neurosci*. 2006; **26**(26): 7035–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. **F** Ashrafi G, Schlehe JS, LaVoie MJ, *et al.*: **Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin.** *J Cell Biol*. 2014; **206**(5): 655–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
14. Guo X, Macleod GT, Wellington A, *et al.*: **The GTPase dMiro is required for axonal transport of mitochondria to *Drosophila* synapses.** *Neuron*. 2005; **47**(3): 379–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. **F** Nguyen TT, Oh SS, Weaver D, *et al.*: **Loss of Miro1-directed mitochondrial movement results in a novel murine model for neuron disease.** *Proc Natl Acad Sci U S A*. 2014; **111**(35): E3631–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
16. **F** Wang X, Winter D, Ashrafi G, *et al.*: **PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility.** *Cell*. 2011; **147**(4): 893–906.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
17. **F** Macaskill AF, Rinholm JE, Twelvetrees AE, *et al.*: **Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses.** *Neuron*. 2009; **61**(4): 541–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
18. Baas PW, Deitch JS, Black MM, *et al.*: **Polarity orientation of microtubules in hippocampal neurons: uniformity in the axon and nonuniformity in the dendrite.** *Proc Natl Acad Sci U S A*. 1988; **85**(21): 8335–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Baas PW, Black MM, Banker GA: **Changes in microtubule polarity orientation during the development of hippocampal neurons in culture.** *J Cell Biol*. 1989; **109**(6 Pt 1): 3085–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Heidemann SR, Landers JM, Hamburg MA: **Polarity orientation of axonal microtubules.** *J Cell Biol*. 1981; **91**(3 Pt 1): 661–5.
[PubMed Abstract](#) | [Free Full Text](#)
21. **F** Pilling AD, Horiuchi D, Lively CM, *et al.*: **Kinesin-1 and Dynein are the primary motors for fast transport of mitochondria in *Drosophila* motor axons.** *Mol Biol Cell*. 2006; **17**(4): 2057–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
22. Morris RL, Hollenbeck PJ: **Axonal transport of mitochondria along microtubules and F-actin in living vertebrate neurons.** *J Cell Biol*. 1995; **131**(5): 1315–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Pathak D, Sepp KJ, Hollenbeck PJ: **Evidence that myosin activity opposes microtubule-based axonal transport of mitochondria.** *J Neurosci*. 2010; **30**(26): 8984–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Quintero OA, DiVito MM, Adikes RC, *et al.*: **Human Myo19 is a novel myosin that associates with mitochondria.** *Curr Biol*. 2009; **19**(23): 2008–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Fransson S, Ruusala A, Aspenström P: **The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial trafficking.** *Biochem Biophys Res Commun*. 2006; **344**(2): 500–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. **F** Glater EE, Megeath LJ, Stowers RS, *et al.*: **Axonal transport of mitochondria requires milton to recruit kinesin heavy chain and is light chain independent.** *J Cell Biol*. 2006; **173**(4): 545–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
27. **F** Giot L, Bader JS, Brouwer C, *et al.*: **A protein interaction map of *Drosophila melanogaster*.** *Science*. 2003; **302**(5651): 1727–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
28. **F** Stowers RS, Megeath LJ, Górski-Andrzejak J, *et al.*: **Axonal transport of mitochondria to synapses depends on milton, a novel *Drosophila* protein.** *Neuron*. 2002; **36**(6): 1063–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
29. Cai Q, Gerwin C, Sheng ZH: **Syntabulin-mediated anterograde transport of mitochondria along neuronal processes.** *J Cell Biol*. 2005; **170**(6): 959–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Suzuki T, Okada Y, Semba S, *et al.*: **Identification of FEZ1 as a protein that interacts with JC virus agnoprotein and microtubules: role of agnoprotein-induced dissociation of FEZ1 from microtubules in viral propagation.** *J Biol Chem*. 2005; **280**(26): 24948–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Patil H, Cho KI, Lee J, *et al.*: **Kinesin-1 and mitochondrial motility control by discrimination of structurally equivalent but distinct subdomains in Ran-GTP-binding domains of Ran-binding protein 2.** *Open Biol*. 2013; **3**(3): 120183.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Cho KI, Cai Y, Yi H, *et al.*: **Association of the kinesin-binding domain of RanBP2 to KIF5B and KIF5C determines mitochondria localization and function.** *Traffic*. 2007; **8**(12): 1722–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Fujita T, Maturana AD, Ikuta J, *et al.*: **Axonal guidance protein FEZ1 associates with tubulin and kinesin motor protein to transport mitochondria in neurites of NGF-stimulated PC12 cells.** *Biochem Biophys Res Commun*. 2007; **361**(3): 605–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Ikuta J, Maturana A, Fujita T, *et al.*: **Fasciculation and elongation protein zeta-1 (FEZ1) participates in the polarization of hippocampal neuron by controlling the mitochondrial motility.** *Biochem Biophys Res Commun*. 2007; **353**(1): 127–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Nangaku M, Sato-Yoshitake R, Okada Y, *et al.*: **KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria.** *Cell*. 1994; **79**(7): 1209–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Tanaka K, Sugiura Y, Ichishita R, *et al.*: **KLP6: a newly identified kinesin that regulates the morphology and transport of mitochondria in neuronal cells.** *J Cell Sci*. 2011; **124**(pt 4): 2457–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Wozniak MJ, Melzer M, Dörner C, *et al.*: **The novel protein KBP regulates mitochondria localization by interaction with a kinesin-like protein.** *BMC Cell Biol*. 2005; **6**: 35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Lyons DA, Naylor SG, Mercurio S, *et al.*: **KBP is essential for axonal structure, outgrowth and maintenance in zebrafish, providing insight into the cellular basis of Goldberg-Shprintzen syndrome.** *Development*. 2008; **135**(3): 599–608.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. **F** van Spronsen M, Mikhaylova M, Lipka J, *et al.*: **TRAK/Milton motor-adaptor proteins steer mitochondrial trafficking to axons and dendrites.** *Neuron*. 2013; **77**(3): 485–502.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
40. **F** Shneyer BI, Ušaj M, Henn A: **Myo19 is an outer mitochondrial membrane motor and effector of starvation-induced filopodia.** *J Cell Sci*. 2016; **129**(3): 543–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**

41. **F** Sung JY, Engmann O, Teylan MA, *et al.*: **WAVE1 controls neuronal activity-induced mitochondrial distribution in dendritic spines.** *Proc Natl Acad Sci U S A.* 2008; **105**(8): 3112–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
42. **F** Kang JS, Tian JH, Pan PY, *et al.*: **Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation.** *Cell.* 2008; **132**(1): 137–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
43. Chen YM, Gerwin C, Sheng ZH: **Dynein light chain LC8 regulates syntaphilin-mediated mitochondrial docking in axons.** *J Neurosci.* 2009; **29**(30): 9429–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Chen Y, Sheng ZH: **Kinesin-1-syntaphilin coupling mediates activity-dependent regulation of axonal mitochondrial transport.** *J Cell Biol.* 2013; **202**(2): 351–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. **F** van Bergeijk P, Adrian M, Hoogenraad CC, *et al.*: **Optogenetic control of organelle transport and positioning.** *Nature.* 2015; **518**(7537): 111–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
46. **F** Su B, Ji YS, Sun XL, *et al.*: **Brain-derived neurotrophic factor (BDNF)-induced mitochondrial motility arrest and presynaptic docking contribute to BDNF-enhanced synaptic transmission.** *J Biol Chem.* 2014; **289**(3): 1213–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
47. Pekkumaz G, Trinidad JC, Wang X, *et al.*: **Glucose regulates mitochondrial motility via Milton modification by O-GlcNAc transferase.** *Cell.* 2014; **158**(1): 54–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. **F** Lai YC, Kondapalli C, Lehneck R, *et al.*: **Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1.** *EMBO J.* 2015; **34**(22): 2840–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
49. **F** Liu S, Sawada T, Lee S, *et al.*: **Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria.** *PLoS Genet.* 2012; **8**(3): e1002537.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
50. Tsai PI, Course MM, Lovas JR, *et al.*: **PINK1-mediated phosphorylation of Miro inhibits synaptic growth and protects dopaminergic neurons in *Drosophila*.** *Sci Rep.* 2014; **4**: 6962.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. **F** Chan NC, Salazar AM, Pham AH, *et al.*: **Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy.** *Hum Mol Genet.* 2011; **20**(9): 1726–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
52. **F** Chen Y, Dorn GW 2nd: **PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria.** *Science.* 2013; **340**(6131): 471–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
53. Poole AC, Thomas RE, Yu S, *et al.*: **The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway.** *PLoS One.* 2010; **5**(4): e10054.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. **F** Tanaka A, Cleland MM, Xu S, *et al.*: **Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin.** *J Cell Biol.* 2010; **191**(7): 1367–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. Ziviani E, Tao RN, Whitworth AJ: ***Drosophila* parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin.** *Proc Natl Acad Sci U S A.* 2010; **107**(11): 5018–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Pickrell AM, Youle RJ: **The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease.** *Neuron.* 2015; **85**(2): 257–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. **F** Narendra D, Walker JE, Youle R: **Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism.** *Cold Spring Harb Perspect Biol.* 2012; **4**(11): pii: a011338.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
58. Kornmann B: **Quality control in mitochondria: use it, break it, fix it, trash it.** *F1000Prime Rep.* 2014; **6**: 15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Li Y, Lim S, Hoffman D, *et al.*: **HUMMR, a hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial distribution and transport.** *J Cell Biol.* 2009; **185**(6): 1065–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. López-Doménech G, Serrat R, Mirra S, *et al.*: **The Eutherian *Armcx* genes regulate mitochondrial trafficking in neurons and interact with Miro and Trak2.** *Nat Commun.* 2012; **3**: 814.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Misko A, Jiang S, Węgorzewska I, *et al.*: **Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex.** *J Neurosci.* 2010; **30**(12): 4232–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. **F** Liu X, Weaver D, Shirihai O, *et al.*: **Mitochondrial 'kiss-and-run': interplay between mitochondrial motility and fusion-fission dynamics.** *EMBO J.* 2009; **28**(20): 3074–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
63. Chada SR, Hollenbeck PJ: **Mitochondrial movement and positioning in axons: the role of growth factor signaling.** *J Exp Biol.* 2003; **206**(Pt 12): 1985–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. **F** Chada SR, Hollenbeck PJ: **Nerve growth factor signaling regulates motility and docking of axonal mitochondria.** *Curr Biol.* 2004; **14**(14): 1272–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
65. Minin AA, Kulik AV, Gyoeva FK, *et al.*: **Regulation of mitochondria distribution by RhoA and formins.** *J Cell Sci.* 2006; **119**(Pt 4): 659–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Mironov SL: **ADP regulates movements of mitochondria in neurons.** *Biophys J.* 2007; **92**(8): 2944–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Mironov SL: **Complexity of mitochondrial dynamics in neurons and its control by ADP during synaptic activity.** *Int J Biochem Cell Biol.* 2009; **41**(10): 2005–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. **F** Ogawa F, Murphy LC, Malavasi EL, *et al.*: **NDE1 and GSK3 β Associate with TRAK1 and Regulate Axonal Mitochondrial Motility: Identification of Cyclic AMP as a Novel Modulator of Axonal Mitochondrial Trafficking.** *ACS Chem Neurosci.* 2016; **7**(5): 553–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
69. **F** Tao K, Matsuki N, Koyama R: **AMP-activated protein kinase mediates activity-dependent axon branching by recruiting mitochondria to axon.** *Dev Neurobiol.* 2014; **74**(6): 557–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
70. **F** Morfini G, Szebenyi G, Elluru R, *et al.*: **Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility.** *EMBO J.* 2002; **21**(3): 281–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
71. Chen S, Owens GC, Edelman DB: **Dopamine inhibits mitochondrial motility in hippocampal neurons.** *PLoS One.* 2008; **3**(7): e2804.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. **F** Gao FJ, Hebbar S, Gao XA, *et al.*: **GSK-3 β Phosphorylation of Cytoplasmic Dynein Reduces Ndel1 Binding to Intermediate Chains and Alters Dynein Motility.** *Traffic.* 2015; **16**(9): 941–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
73. de Vos KJ, Grierson AJ, Ackerley S, *et al.*: **Role of axonal transport in neurodegenerative diseases.** *Annu Rev Neurosci.* 2008; **31**: 151–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Morfini GA, Burns M, Binder LI, *et al.*: **Axonal transport defects in neurodegenerative diseases.** *J Neurosci.* 2009; **29**(41): 12776–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Dehesi S, Pasqualotto BA, Rintoul GL: **Mitochondrial trafficking in neuropsychiatric diseases.** *Neurobiol Dis.* 2013; **51**: 66–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Gilley J, Seereeram A, Ando K, *et al.*: **Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse.** *Neurobiol Aging.* 2012; **33**(3): 621.e1–621.e15.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. **F** Valente EM, Abou-Sleiman PM, Caputo V, *et al.*: **Hereditary early-onset Parkinson's disease caused by mutations in PINK1.** *Science.* 2004; **304**(5674): 1158–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
78. Kitada T, Asakawa S, Hattori N, *et al.*: **Mutations in the *parkin* gene cause autosomal recessive juvenile parkinsonism.** *Nature.* 1998; **392**(6676): 605–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Pigino G, Morfini G, Pelsman A, *et al.*: **Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport.** *J Neurosci.* 2003; **23**(11): 4499–508.
[PubMed Abstract](#)
80. **F** Stokin GB, Lillo C, Falzone TL, *et al.*: **Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease.** *Science.* 2005; **307**(5713): 1282–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
81. Rui Y, Tiwari P, Xie Z, *et al.*: **Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons.** *J Neurosci.* 2006; **26**(41): 10480–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Vossel KA, Zhang K, Brodbeck J, *et al.*: **Tau reduction prevents Abeta-induced defects in axonal transport.** *Science.* 2010; **330**(6001): 198.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. Calkins MJ, Reddy PH: **Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons.** *Biochim Biophys Acta.* 2011; **1812**(4): 507–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Sasaki S, Iwata M: **Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis.** *Neurology.* 1996; **47**(2): 535–40.
[PubMed Abstract](#) | [Publisher Full Text](#)

85. De Vos KJ, Chapman AL, Tennant ME, *et al.*: **Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content.** *Hum Mol Genet.* 2007; **16**(22): 2720–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
86. **F** Magrané J, Hervias I, Henning MS, *et al.*: **Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities.** *Hum Mol Genet.* 2009; **18**(23): 4552–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
87. **F** Baldwin KR, Godena VK, Hewitt VL, *et al.*: **Axonal transport defects are a common phenotype in *Drosophila* models of ALS.** *Hum Mol Genet.* 2016; pii: ddw105.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
88. **F** Magrané J, Cortez C, Gan WB, *et al.*: **Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models.** *Hum Mol Genet.* 2014; **23**(6): 1413–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
89. Shi P, Ström AL, Gal J, *et al.*: **Effects of ALS-related SOD1 mutants on dynein- and KIF5-mediated retrograde and anterograde axonal transport.** *Biochim Biophys Acta.* 2010; **1802**(9): 707–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. **F** Shan X, Chiang PM, Price DL, *et al.*: **Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of *TDP-43* transgenic mice.** *Proc Natl Acad Sci U S A.* 2010; **107**(37): 16325–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
91. **F** Bosco DA, Morfini G, Karabacak NM, *et al.*: **Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS.** *Nat Neurosci.* 2010; **13**(11): 1396–403.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
92. Trushina E, Dyer RB, Badger JD 2nd, *et al.*: **Mutant huntingtin impairs axonal trafficking in mammalian neurons *in vivo* and *in vitro*.** *Mol Cell Biol.* 2004; **24**(18): 8195–209.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
93. Chang DT, Rintoul GL, Pandipati S, *et al.*: **Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.** *Neurobiol Dis.* 2006; **22**(2): 388–400.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. **F** Orr AL, Li S, Wang CE, *et al.*: **N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking.** *J Neurosci.* 2008; **28**(11): 2783–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
95. **F** Baloh RH, Schmidt RE, Pestronk A, *et al.*: **Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusins 2 mutations.** *J Neurosci.* 2007; **27**(2): 422–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
96. Ferreira F, Quattrini A, Pirozzi M, *et al.*: **Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport.** *J Clin Invest.* 2004; **113**(2): 231–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
97. Kasher PR, De Vos KJ, Wharton SB, *et al.*: **Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients.** *J Neurochem.* 2009; **110**(1): 34–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. Millar JK, Wilson-Annan JC, Anderson S, *et al.*: **Disruption of two novel genes by a translocation co-segregating with schizophrenia.** *Hum Mol Genet.* 2000; **9**(9): 1415–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
99. Atkin TA, MacAskill AF, Brandon NJ, *et al.*: **Disrupted in Schizophrenia-1 regulates intracellular trafficking of mitochondria in neurons.** *Mol Psychiatry.* 2011; **16**(2): 122–4, 121.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. **F** Ogawa F, Malavasi EL, Crummie DK, *et al.*: **DISC1 complexes with TRAK1 and Miro1 to modulate anterograde axonal mitochondrial trafficking.** *Hum Mol Genet.* 2014; **23**(4): 906–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
101. Miyoshi K, Honda A, Baba K, *et al.*: **Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth.** *Mol Psychiatry.* 2003; **8**(7): 685–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Belmaker RH, Agam G: **Major depressive disorder.** *N Engl J Med.* 2008; **358**(1): 55–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
103. **F** Takihara Y, Inatani M, Eto K, *et al.*: ***In vivo* imaging of axonal transport of mitochondria in the diseased and aged mammalian CNS.** *Proc Natl Acad Sci U S A.* 2015; **112**(33): 10515–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
104. Misgeld T, Kerschensteiner M, Bareyre FM, *et al.*: **Imaging axonal transport of mitochondria *in vivo*.** *Nat Methods.* 2007; **4**(7): 559–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
105. **F** Bolea I, Gan WB, Manfredi G, *et al.*: **Imaging of mitochondrial dynamics in motor and sensory axons of living mice.** *Methods Enzymol.* 2014; **547**: 97–110.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
106. Wang X, Schwarz TL: **Imaging axonal transport of mitochondria.** *Methods Enzymol.* 2009; **457**: 319–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Plucinska G, Paquet D, Hruscha A, *et al.*: ***In vivo* imaging of disease-related mitochondrial dynamics in a vertebrate model system.** *J Neurosci.* 2012; **32**(46): 16203–12.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Eugenia Trushina**

Department of Neurology, Mayo Clinic, Rochester, MN, USA

Competing Interests: No competing interests were disclosed.

2. **Michael B. Robinson**

Children's Hospital of Philadelphia Research Institute, University of Pennsylvania, Philadelphia, PA, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research